EUVIMEDEUVIMED entdecken
Open Access

Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals

Medikamente zur Behandlung der Opioidkonsumstörung und Behandlungsverbleib bei schwangeren Personen

Valerie S Ganetsky, Noa Krawczyk, Alene Kennedy-Hendricks

JAMA Network Open · 21.04.2025 · 8 (4) · e256069

DOI: 10.1001/jamanetworkopen.2025.6069 ↗

Auf einen Blick

Bei schwangeren Personen mit Opioidkonsumstörung war die Einbindung von MOUD mit höherem 6-Monats-Verbleib verbunden. Der Verbleib blieb insgesamt niedrig.

Fragestellung

Ist die Einbindung von MOUD in die Behandlung mit 6-Monats-Behandlungsverbleib bei schwangeren Personen mit OUD assoziiert?

Methode

Querschnittsstudie mit gepoolten Daten von 2015 bis 2021 aus dem Treatment Episode Data Set-Discharges; Analyse mit inverse probability of treatment-weighted logistischer Regression.

Ergebnisse

MOUD war mit höheren Chancen für 6-Monats-Verbleib verbunden als ohne MOUD: adjustierte Odds Ratio 1,86 (95 %-KI 1,72-2,01). Die adjustierte Wahrscheinlichkeit betrug 43,1 % vs. 28,9 %.

Schlussfolgerung der Autor:innen

Die Einbindung von MOUD war bei schwangeren Personen mit OUD mit einer signifikanten Verbesserung des Behandlungsverbleibs verbunden. Der Verbleib blieb während der HPSO-Ära dennoch niedrig.

Kernaussagen

  • MOUD ging mit höherem 6-Monats-Verbleib einher.
  • Adjustierte Odds Ratio: 1,86 (95 %-KI 1,72-2,01).
  • Die adjustierte Wahrscheinlichkeit lag bei 43,1 % vs. 28,9 %.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 21.04.2025. Verfasst von Valerie S Ganetsky und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment, Pregnancy Complications, Retention in Care. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treatment retention for pregnant individuals with opioid use disorder (OUD) is critical, especially during the high-potency synthetic opioid (HPSO) era. Current data on the relationship between medication for opioid use disorder (MOUD) receipt in specialty substance use treatment facilities and retention are needed for this population.

Objective

To examine the association between MOUD inclusion in treatment and 6-month treatment retention among pregnant individuals with OUD in publicly funded specialty treatment facilities during the HPSO era. Design, Setting, and Participants This cross-sectional study pooled data from January 1, 2015, to December 31, 2021, from the Treatment Episode Data Set-Discharges, a national dataset managed by the Substance Abuse and Mental Health Services Administration that tracks annual discharges from state-licensed, publicly funded substance use treatment facilities. Individuals who were pregnant at the time of admission, reported an opioid (heroin, nonprescription methadone, or other opiates and synthetics) as their primary substance, and were discharged from ambulatory, nonintensive outpatient facilities were included. Data were analyzed November 2023 to April 2024. Exposure MOUD inclusion in a treatment episode. Main Outcomes and Measures The main outcome was treatment retention (length of stay >6 months vs ≤6 months). To account for the nonrandom assignment to MOUD, inverse probability of treatment–weighted logistic regression models were estimated adjusting for sociodemographics; substance use, mental health, and treatment history; treatment admission–related variables; census division; state policy characteristics; and year fixed effects.

Results

Of 29 981 treatment episodes, most involved individuals aged 25 to 34 years (19 106 [63.7%]). Approximately two-thirds of 29 071 episodes in the final analysis (19 884 [68.4%]) included MOUD across all study years. From 2015 to 2021, MOUD inclusion in treatment episodes increased by 9.1 percentage points, from 65.0% to 74.1%. Treatment episodes with MOUD were associated with greater odds of 6-month treatment retention compared with those without MOUD (adjusted odds ratio, 1.86 [95% CI, 1.72-2.01]). This finding translated to an estimated 14.2 percentage point greater adjusted probability of 6-month retention among treatment episodes with MOUD (43.1%) vs those without it (28.9%). Conclusions and Relevance In this cross-sectional study of treatment episodes from ambulatory, nonintensive facilities, MOUD inclusion among pregnant individuals was associated with significant improvements in treatment retention. However, retention remained low during the HPSO era. These findings underscore the importance of MOUD in improving OUD-related outcomes in this high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersOpiate Substitution TreatmentPregnancy ComplicationsRetention in CareHumansFemalePregnancyCross-Sectional StudiesAdultMethadone

Substanzen

Methadone

Autor:innen und Institutionen

  • Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Center for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, New York.

Zitieren

APA

Ganetsky, V. S., Krawczyk, N., & Kennedy-Hendricks, A. (2025). Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals. JAMA Network Open, 8(4), e256069. https://doi.org/10.1001/jamanetworkopen.2025.6069

Vancouver

Ganetsky VS, Krawczyk N, Kennedy-Hendricks A. Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals. JAMA Network Open. 2025;8(4):e256069. doi:10.1001/jamanetworkopen.2025.6069

BibTeX
@article{Ganetsky2025,
  author = {Ganetsky, Valerie S and Krawczyk, Noa and Kennedy-Hendricks, Alene},
  title = {Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {4},
  pages = {e256069},
  doi = {10.1001/jamanetworkopen.2025.6069}
}
Kostenlos starten →